UK markets closed
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • FTSE 250

    23,608.63
    -0.16 (-0.00%)
     
  • AIM

    1,268.23
    +1.25 (+0.10%)
     
  • GBP/EUR

    1.1714
    +0.0053 (+0.46%)
     
  • GBP/USD

    1.3706
    +0.0026 (+0.19%)
     
  • BTC-GBP

    31,580.65
    -298.13 (-0.94%)
     
  • CMC Crypto 200

    1,078.14
    -23.38 (-2.12%)
     
  • S&P 500

    4,444.32
    -11.16 (-0.25%)
     
  • DOW

    34,950.89
    +152.89 (+0.44%)
     
  • CRUDE OIL

    75.31
    +1.33 (+1.80%)
     
  • GOLD FUTURES

    1,751.60
    -0.10 (-0.01%)
     
  • NIKKEI 225

    30,240.06
    -8.75 (-0.03%)
     
  • HANG SENG

    24,208.78
    +16.62 (+0.07%)
     
  • DAX

    15,573.88
    +42.13 (+0.27%)
     
  • CAC 40

    6,650.91
    +12.45 (+0.19%)
     

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

PASADENA, Calif., July 14, 2021--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021, the Compensation Committee of the Company’s Board of Directors approved "inducement" grants to 42 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 157,000 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005350/en/

Contacts

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com

Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361
jo@lifescicomms.com
www.lifescicommunications.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting